WebEvofem Clocks 42% Growth For Its On-Demand Birth Control Product. Evofem Biosciences Inc's (NASDAQ: EVFM) Q2 Phexxi sales increased 42% Y/Y to $6.0 million, reflecting higher ex-factory sales and lower gross-to-net adjustments of 40%. The company's operating expense was reduced by 8% to $30 million and improved loss from operations by 16% to ... WebMay 20, 2024 · Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock, 12,835,000 pre ...
EVFM Stock Price and Chart — OTC:EVFM — TradingView
WebMay 7, 2024 · Evofem Biosciences, Inc. (OTCQB:EVFM) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ETCompany ParticipantsAmy Raskopf - Vice President of Investor RelationsSaundra Pelletier - Chief... WebMay 4, 2024 · SAN DIEGO, May 4, 2024 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) ("Evofem" or the "Company"), today reported financial results for the … dell precision t series workstations
Why This Woman Might Disrupt the Condom (and the Pill) Inc.com
WebSep 8, 2024 · SAN DIEGO, Sept. 8, 2024 /PRNewswire/ --Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Phexxi ™ (lactic acid, citric acid and potassium bitartrate), the first and only non-hormonal prescription vaginal gel is now available in the United States for the prevention of pregnancy in females of reproductive potential for use … WebApr 11, 2024 · Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma Financing to fund pre-launch commercialization activities ... WebOct 12, 2024 · A biotech with an approved non-hormonal birth control gel had hoped it would be at the FDA's doorsteps in early 2024 to request a label expansion into STI prevention. But those ambitions were ... dell precision workstation mini tower 3620